Synflorix 0,5 mL FC tablets.
PDF Leaflet Revision Date: 14 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunisation against pneumococcal disease in infants and children.
Dosage (summary)
Infants 6 weeks to 6 months: 3 doses (0.5 mL) at least 1 month apart; booster at 9 months.
Special Populations
- HIV infection
- Sickle cell disease
- Splenic dysfunction
Pregnancy & Breastfeeding
Not intended for adults; safety in pregnancy/lactation not established.
Key Drug Interactions
- Concomitant administration with DTPa, HBV, IPV, Hib vaccines
Contraindications
- Hypersensitivity to any component of the vaccine
Common side effects
- Redness at injection site
- Irritability
- Pain at injection site
Counselling Points
- Review medical history before vaccination
- Monitor for fainting
- Do not administer intravascularly
Serious warnings
- Risk of anaphylaxis
- Postpone in acute febrile illness
- Caution in coagulation disorders
Important Disclaimer
The Synflorix 0,5 mL FC tablets. professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
